Invesco Ltd. Trims Position in Ascendis Pharma A/S (NASDAQ:ASND)

Invesco Ltd. reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,156,013 shares of the biotechnology company's stock after selling 6,232 shares during the period. Invesco Ltd. owned approximately 1.90% of Ascendis Pharma A/S worth $159,148,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership boosted its holdings in shares of Ascendis Pharma A/S by 0.9% in the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after acquiring an additional 39,309 shares during the last quarter. American Century Companies Inc. boosted its holdings in Ascendis Pharma A/S by 17.5% in the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock valued at $56,072,000 after purchasing an additional 60,548 shares during the last quarter. ARS Investment Partners LLC grew its position in Ascendis Pharma A/S by 0.9% during the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company's stock worth $36,549,000 after purchasing an additional 2,369 shares during the period. New York State Common Retirement Fund raised its stake in shares of Ascendis Pharma A/S by 14.0% during the 4th quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock valued at $28,151,000 after buying an additional 25,164 shares during the last quarter. Finally, abrdn plc lifted its holdings in shares of Ascendis Pharma A/S by 18.3% in the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after buying an additional 28,967 shares during the period.

Ascendis Pharma A/S Trading Up 4.4 %

ASND traded up $6.90 on Friday, hitting $165.05. 629,215 shares of the company's stock were exchanged, compared to its average volume of 479,950. The firm has a 50-day moving average price of $151.09 and a 200-day moving average price of $138.07. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of -23.25 and a beta of 0.54. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on ASND shares. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target for the company. Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S in a report on Wednesday. They set an "outperform" rating and a $205.00 target price for the company. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $204.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.